Sugi Predict

Sugi Predict / Compounds / SCHEMBL2208124

SCHEMBL2208124

SCHEMBL2208124

CN(C)/C=C/C(=O)c1ccc(F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 1.00
▸ CYP2C19 P33261 2/20 1.00
▸ MAPT P10636 6/20 0.68
▸ RAB9A P51151 5/20 0.68
▸ LMNA P02545 3/20 0.68
▸ RECQL P46063 2/20 0.68
▸ HPGD P15428 2/20 0.68
▸ ALOX12 P18054 1/20 0.68
▸ ALDH1A1 P00352 7/20 0.64
▸ HTT P42858 1/20 0.62
▸ NPC1 O15118 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ POLB P06746 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ HSP90AA1 P07900 1/20 0.58
▸ GAA P10253 1/20 0.57
▸ TNFRSF1A P19438 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24119203 1.00 CYP1A2 (1.00) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL2208129 1.00 CYP1A2 (1.00) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL13270534 0.90 CYP1A2 (0.81) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL13030714 0.90 CYP1A2 (0.81) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL3128331 0.90 CYP1A2 (0.81) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL23251385 0.90 MAPT (0.81) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL1186588 0.82 MAPT (0.70) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL1186589 0.82 MAPT (0.70) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL801273 0.82 MAPT (0.70) CYP1A2CYP2C19MAPTRAB9ALMNA
SCHEMBL7364598 0.82 MAPT (0.70) CYP1A2CYP2C19MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080001-A Perfluoroalkyl substituted pyrimido [1,2-b ] indazole ketone compound and preparation method thereof — 2026-05-26 — — CN claimed
CN-119285450-A Preparation method of 1-hydroxy-2-naphthaldehyde derivative 西北工业大学 2025-01-10 — — CN claimed
CN-119019332-A 1, 5-Disubstituted-4-bromopyrazole compound and preparation method and application thereof 赣南师范大学 2024-11-26 — — CN claimed
CN-118834161-A Preparation method of 3-sulfonyl-5-acetyl-1, 4 dihydropyridine compound 西北工业大学 2024-10-25 — — CN claimed
CN-116396145-A Preparation method of 9-phenanthrene phenol compound 西北工业大学 2023-07-07 — — CN claimed
EP-3983411-B1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS PI INDUSTRIES LTD (IN) 2026-05-27 — — EP disclosed
CN-122080001-A Perfluoroalkyl substituted pyrimido [1,2-b ] indazole ketone compound and preparation method thereof — 2026-05-26 — — CN disclosed
US-20250275965-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) 2025-09-04 — — US disclosed
US-12384787-B2 Fused heterocyclic compounds and their use as pest control agents PI INDUSTRIES LTD (IN) 2025-08-12 — — US disclosed
CN-119285450-A Preparation method of 1-hydroxy-2-naphthaldehyde derivative 西北工业大学 2025-01-10 — — CN disclosed
CN-119019332-A 1, 5-Disubstituted-4-bromopyrazole compound and preparation method and application thereof 赣南师范大学 2024-11-26 — — CN disclosed
CN-118834161-A Preparation method of 3-sulfonyl-5-acetyl-1, 4 dihydropyridine compound 西北工业大学 2024-10-25 — — CN disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 — — US disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 — — US disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 — — US disclosed
WO-2007028132-A2 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2007-03-08 — — WO disclosed
US-5110831-A Antiinflammatory agents; leukotriene antagonists DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-05-05 — — US disclosed
US-4755599-A 3-phenyl-2-propeneamine derivatives, their preparation and composition containing them RHONE-POULENC SANTE (FR) 1988-07-05 — — US disclosed
US-4686309-A ANTIDEPRESSANTS RHONE-POULENC SANTE (FR) 1987-08-11 — — US disclosed
US-4209621-A TRANQUILIZERS AMERICAN CYANAMID COMPANY (US) 1980-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists HTR2C, HTR3B, HTR1A CYP1A2 216/4885CYP2C19 173/4885MAPT 4671/4885
US-12384787-B2 Fused heterocyclic compounds and their use as pest control agents DDT, ACHE, KEAP1 CYP1A2 87/4885CYP2C19 296/4885MAPT 4270/4885
US-20250275965-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS PACSIN2, CSNK1A1, CSNK1G3 CYP1A2 3812/4885CYP2C19 3296/4885MAPT 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.